Prothena - Stock Price History | PRTA

Historical daily share price chart and data for Prothena since 2021 adjusted for splits. The latest closing stock price for Prothena as of October 22, 2021 is 61.61.
  • The all-time high Prothena stock closing price was 78.89 on September 23, 2021.
  • The Prothena 52-week high stock price is 79.75, which is 29.4% above the current share price.
  • The Prothena 52-week low stock price is 10.72, which is 82.6% below the current share price.
  • The average Prothena stock price for the last 52 weeks is 34.74.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Prothena Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 11.7699 15.6300 15.7700 7.5400 12.0100 -24.13%
2019 10.5694 10.5000 17.0100 6.8900 15.8300 53.69%
2018 20.4841 37.8000 45.0400 8.7300 10.3000 -72.53%
2017 54.5062 49.7900 67.7500 35.4400 37.4900 -23.79%
2016 47.9551 62.2200 67.6400 30.1200 49.1900 -27.78%
2015 46.1863 20.3500 75.3100 19.0500 68.1100 228.08%
2014 24.7390 28.1000 48.3000 17.2600 20.7600 -21.72%
2013 14.7389 7.0000 29.0400 5.8400 26.5200 261.80%
2012 6.9833 7.2000 7.3300 6.8000 7.3300 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.722B $0.001B
Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson's disease, MCAM for Inflammatory disease and Metastatic Cancer and Tau for Alzheimer's disease. Prothena Corporation plc is headquartered in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76